Two Biogen therapies prove effective for treating hemophilia
“As the first prolonged half-life therapies, Eloctate and Alprolix have shown low rates in both joint bleeding and overall annualized bleeding episodes,” Dr. Kate Dawson, vice president of U.S. medical at Biogen, said. “Their ability to reduce bleed rates, which may translate into the potential for reducing some joint disease, continues to reaffirm their clinical value for people living with hemophilia A and B.”
Most bleeding events in hemophilia A and B patients are in their joints, which can lead to chronic joint disease. Hemophilia is a rare genetic condition in which the blood does not clot.
The tests on Eloctate and Alprolix were done by scientists from Biogen and Swedish Orphan Biovitrum (Sobi) on subjects that had three or more bleeding episodes over a three or six-month period. Results were presented at the recent 57th American Society of Hematology Annual Meeting and Exposition in Orlando, Florida.
“Understanding the impact of Eloctate and Alprolix on people with target joint bleeds provides further insight into their value in a real-world setting,” Dr. Birgitte Volck, chief medical officer at Sobi, said. “These new results from the post hoc analyses highlight the value of extended half-life therapy in managing and controlling bleeds, adding to the body of robust clinical data and the longest real-world experience of any extended half-life therapy to date."
For more information, visit www.eloctate.com or www.alprolix.com.
Organizations in this story
Biogen 225 Binney St Cambridge, MA 02142